{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Malensek S"],"funding":["The Slovenian Research and Innovation Agency","Horizon Europe"],"pagination":["101535"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12356014"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(3)"],"pubmed_abstract":["Cardiovascular diseases, especially atherosclerosis, are the main cause of death in the whole world. The risk can be reduced by lowering the serum low-density lipoprotein cholesterol by targeting proprotein convertase 9 (PCSK9) through genome editing or neutralization by monoclonal antibodies. Vaccination against PCSK9 represents an alternative with potentially long-lasting efficacy, but must overcome the challenge of immunogenicity against the endogenous protein, which can also elicit lower antibody response due to B cell tolerance. In contrast to the previously reported weakly immunogenic PCSK9 peptides, we have developed a designed chimeric PCSK9 that maintains the surface epitopes and elicits a B cell immune response with PCSK9-specific antibodies, comparable to human-based vaccines, b"],"journal":["Molecular therapy. Methods & clinical development"],"pubmed_title":["Engineering chimeric PCSK9 for a vaccine against atherosclerosis."],"pmcid":["PMC12356014"],"funding_grant_id":["101059842","P4-0176","J3-4526"],"pubmed_authors":["Lainscek D","Esih H","Blinc A","Urbanc AG","Malensek S","Orehek S","Fink T","Jerala R"],"additional_accession":[]},"is_claimable":false,"name":"Engineering chimeric PCSK9 for a vaccine against atherosclerosis.","description":"Cardiovascular diseases, especially atherosclerosis, are the main cause of death in the whole world. The risk can be reduced by lowering the serum low-density lipoprotein cholesterol by targeting proprotein convertase 9 (PCSK9) through genome editing or neutralization by monoclonal antibodies. Vaccination against PCSK9 represents an alternative with potentially long-lasting efficacy, but must overcome the challenge of immunogenicity against the endogenous protein, which can also elicit lower antibody response due to B cell tolerance. In contrast to the previously reported weakly immunogenic PCSK9 peptides, we have developed a designed chimeric PCSK9 that maintains the surface epitopes and elicits a B cell immune response with PCSK9-specific antibodies, comparable to human-based vaccines, b","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T12:40:09.497Z","creation":"2026-07-04T03:14:38.915Z"},"accession":"S-EPMC12356014","cross_references":{"pubmed":["40821854"],"doi":["10.1016/j.omtm.2025.101535"]}}